Human Acellular Vessel (HAV)

Phase 2/3Active

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Trauma

Conditions

Trauma, Vascular System Injury

Trial Timeline

Sep 1, 2018 → Sep 1, 2027

NCT ID

NCT03005418

About Human Acellular Vessel (HAV)

Human Acellular Vessel (HAV) is a phase 2/3 stage product being developed by Humacyte for Trauma. The current trial status is active. This product is registered under clinical trial identifier NCT03005418. Target conditions include Trauma, Vascular System Injury.

What happened to similar drugs?

8 of 18 similar drugs in Trauma were approved

Approved (8) Terminated (5) Active (6)

🔄Transdermal Patch + Loxoprofen sodium + Placebo (for loxoprofen sodium) + Placebo (for transdermal patch)Daiichi SankyoPhase 3

🔄Duloxetine hydrochlorideEli LillyPhase 3

✅Galcanezumab-GnlmEli LillyApproved

✅Placebo + sertralineJohnson & JohnsonApproved

🔄Quetiapine Fumarate + quetiapine fumarate placeboAstraZenecaPhase 3

✅Adjunctive asenapineMerckApproved

✅AlendronateMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03005418	Phase 2/3	Active	Sep 1, 2018	Sep 1, 2027	Trauma
NCT03183245	Phase 3	Completed	Sep 29, 2017	Jun 19, 2025	Renal Failure
NCT02887859	Phase 2	Completed	Dec 20, 2016	Dec 1, 2023	Peripheral Artery Disease
NCT02644941	Phase 3	Completed	May 24, 2016	Sep 1, 2023	Renal Failure

Competing Products

20 competing products in Trauma

See all competitors

Product	Company	Stage	Hype Score
Duloxetine + Sugar pill	Eli Lilly	Phase 2	27
Neurosteroid enantiomer	Oragenics	Phase 2	32
Transdermal Patch + Loxoprofen sodium + Placebo (for loxoprofen sodium) + Placebo (for transdermal patch)	Daiichi Sankyo	Phase 3	40
Celecoxib	Astellas Pharma	Pre-clinical	26
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product	Sun Pharmaceutical	Phase 1	29
Duloxetine hydrochloride	Eli Lilly	Phase 3	36
Galcanezumab-Gnlm	Eli Lilly	Approved	43
SYN117 (nepicastat) + Placebo comparator	Johnson & Johnson	Phase 2	27
Nepicastat + Placebo	Johnson & Johnson	Phase 2	35
JNJ-17299425	Johnson & Johnson	Phase 2	27
Placebo + sertraline	Johnson & Johnson	Approved	35
Quetiapine Fumarate + quetiapine fumarate placebo	AstraZeneca	Phase 3	40
Adjunctive asenapine	Merck	Approved	43
Rizatriptan + Placebo	Merck	Pre-clinical	18
Alendronate	Merck	Approved	39
Iloperidone + Placebo	Novartis	Phase 2	27
AMG 334	Novartis	Phase 2	35
Rivastigmine	Novartis	Phase 3	40
Rivastigmine	Novartis	Approved	43
Balovaptan + Placebo	Roche	Phase 2	35